Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas: Prognostic Factors and Long-Term Results of 155 Patients

Laskar, Siddhartha; Bahl, Gaurav; Puri, Ajay; Agarwal, Manish; Muckaden, Maryann; Patil, Nikhilesh; Jambhekar, Nirmala A.; Gupta, Sudeep; Deshpande, Deepak D.; Shrivastava, Shyam K.; Dinshaw, Ketayun A.

doi:10.1245/s10434-006-9137-2

Cited by 37 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequent toxicity was poor wound healing and infection, especially in the setting of previous external beam radiation treatment. Local control was high with a rate similar to that of other studies reporting outcomes of post-operative radiation therapy [3, 4]. The HDR brachytherapy was well-tolerated by all patients.…”

Section: Discussionsupporting

confidence: 80%

Clinical Investigations Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report

Bradley¹,

Kleinman²,

Rownd³

et al. 2011

jcb

View full text Add to dashboard Cite

PurposeAdjuvant high-dose-rate brachytherapy (HDRBT) offers advantages over low dose rate brachytherapy (LDRBT), although there are little data on local tumor control and treatment related toxicity. We report outcome in patients with primary, recurrent, and metastatic extremity and superficial trunk soft tissue sarcoma.Material and methodsEleven patients (12 sites) with intermediate or high grade sarcoma were treated with adjuvant HDRBT following surgical resection. Patients were treated at 3.4 Gy fractions delivered twice daily to a total dose of 34 Gy (1 patient received 9 fractions).ResultsWith median follow-up of 20.8 months, 1 patient developed a local recurrence. 2-year local control and overall survival are 89% and 71%, respectively. Wound complications occurred in 3 sites. Two of the wound complications developed in the area of previous external beam radiotherapy (EBRT).ConclusionSurgical resection followed by HDRBT is associated with excellent early local tumor control and acceptable wound complication.

show abstract

Section: Discussionsupporting

confidence: 80%

Clinical Investigations Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report

Bradley¹,

Kleinman²,

Rownd³

et al. 2011

jcb

View full text Add to dashboard Cite

show abstract

“…Total dose ranges from 12 to 24 Gy depending on the EBRT dose. The local control rates have been found to be almost similar with LDR and HDR, although there is paucity of data (12,19). Pohar et al (19) reported a nonrandomized study in 37 patients and observed 2-year local control rates of 90% and 94% with LDR and HDR, respectively (p 5 0.99).…”

Section: Discussionmentioning

confidence: 99%

“…Pohar et al (19) reported a nonrandomized study in 37 patients and observed 2-year local control rates of 90% and 94% with LDR and HDR, respectively (p 5 0.99). Laskar et al (12) conducted a retrospective analysis and reported equivalent local control and DFS rates with both LDR and HDR.…”

Section: Discussionmentioning

confidence: 99%

Perioperative high-dose-rate interstitial brachytherapy combined with external beam radiation therapy for soft tissue sarcoma

Sharma¹,

Deo²,

Rath³

et al. 2015

Brachytherapy

View full text Add to dashboard Cite

“…Furthermore, the use of EBRT achieves the same survival as radical surgery, without the cost of major functional impairment from amputation or extended resection [4]. Some of published experiences seems to suggest that the use of a boost with brachytherapy (BRT) can further improve local control rate achievable with adjuvant EBRT [5,6,7,8,9,10,11,12].…”

Section: Purposementioning

confidence: 99%

Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas

Cortesi¹,

Frakulli²,

Galuppi³

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

Purpose: The standard primary treatment for soft tissue sarcoma (STS) is a wide surgical resection, preceded or followed by radiotherapy. Purpose of this retrospective study was to assess the efficacy of perioperative brachytherapy (BRT) plus postoperative external beam radiation therapy (EBRT) in patients with intermediate-high risk STS.Material and methods: BRT delivered dose was 20 Gy. External beam radiation therapy was delivered with 3D-technique using multiple beams. The prescribed dose was 46 Gy to the PTV. Neoadjuvant and adjuvant chemotherapy (CHT) was used in patients with potentially chemosensitive histological subtypes. The primary aim of the study was to analyze overall survival (OS) and local control (LC) in a large patient population treated with surgery, perioperative BRT, and adjuvant EBRT ± CHT. Secondary objective was to identify prognostic factors for patients outcome in terms of LC, disease-free survival (DFS), and OS.Results: From 2000 to 2011, 107 patients presenting 2-3 grade (FNLCC) primary or recurrent STS were treated with surgery, perioperative BRT, and adjuvant EBRT ± CHT. Five-year LC and OS were 80.9% and 87.4%, respectively. At univariate analysis, a higher LC was recorded in primary vs. recurrent tumors (p = 0.015), and in lower limb tumors vs. other sites (p = 0.027). An improved DFS was recorded in patients with lower limb tumors vs. other sites (p = 0.034).Conclusions: The combination of BRT and EBRT was able to achieve satisfactory results even in a patients population with intermediate-high risk STS. Patients with recurrent or other than lower limb sited tumors show a worse LC.

show abstract

Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas: Prognostic Factors and Long-Term Results of 155 Patients

Cited by 37 publications

References 24 publications

Clinical Investigations Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report

Clinical Investigations Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report

Perioperative high-dose-rate interstitial brachytherapy combined with external beam radiation therapy for soft tissue sarcoma

Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas

Contact Info

Product

Resources

About